Program
brenipatide
Also written as “Brenipatide” and “LY3537031”.
Its studies are mostly in Depressive Disorder, Major · Irritable Bowel Syndrome · Alcoholism · Obesity · Asthma, led by Eli Lilly.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 1916 open or running | phase 3since Oct 13, 2025 | Nov 24, 2020 | Nov 2026phase 1 · NCT06606106 |
- Named in Eli Lilly’s own pipeline as
Brenipatide
, phase 3, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Nov 24, 2020.
- Aug 27, 2024Phase 1 study in OverweightNCT06606106 · 302 enrolled · United States
- Sep 3, 20253 phase 1 studiesNCT07165015, NCT07165002, NCT07202871
- Oct 13, 20252 phase 3 studies in AlcoholismNCT07219966, NCT07219953
- Oct 20, 20252 phase 2 studiesNCT07219173, NCT07223840
- Nov 21, 2025Phase 2 study in Bipolar DisorderNCT07286175 · 400 planned · United States, Argentina, Brazil and more
- Feb 6, 2026Phase 3 study in Depressive Disorder, MajorNCT07412756 · 1,000 planned · United States, Australia, Brazil and more
- Feb 6, 20262 phase 2 studiesNCT07410507, NCT07420283
- Mar 13, 2026Phase 1 study in ObesityNCT07476118 · 150 enrolled · United States
- Apr 16, 20262 phase 2 studies in Irritable Bowel SyndromeNCT07545772, NCT07545759
- Aug 7, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07759245 · 606 planned · United States, Argentina, Austria and more
- Aug 14, 2026Phase 3 study in Depressive Disorder, MajorNCT07775300 · 1,000 planned · United States, Australia, Brazil and more
- Sep 30, 2026Primary completion moved from 2026-07 to 2026-11Date moved laterphase 1 · +4 months · NCT06606106
- Sep 30, 2026Primary completion moved from 2026-08 to 2026-11Date moved laterphase 1 · +3 months · NCT07165002
- Nov 5, 2026Phase 2 study in Depressive Disorder, MajorNCT07928245 · 330 planned · United States, Bulgaria, Hungary and more
Ahead
- Nov 2026Primary completion: phase 1 study in Hepatic InsufficiencyNCT07165002
- Nov 2026Primary completion: phase 1 study in OverweightNCT06606106
- Feb 2027Primary completion: phase 1 study in ObesityNCT07476118
- Feb 2027Primary completion: phase 2 study in SmokingNCT07223840
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07928245Depressive Disorder, Major · United States, Bulgaria, Hungary and more | 2 | Not yet recruiting | May 2028 | 330 |
| NCT07775300Depressive Disorder, Major · United States, Australia, Brazil and more | 3 | Recruiting | Dec 2028 | 1,000 |
| NCT07759245Pulmonary Disease, Chronic Obstructive · United States, Argentina, Austria and more | 2 | Recruiting | May 2028 | 606 |
| NCT07545772Irritable Bowel Syndrome · United States, Belgium, Canada and more | 2 | Recruiting | Jul 2027 | 342 |
| NCT07545759Irritable Bowel Syndrome · United States, Belgium, Canada and more | 2 | Recruiting | Sep 2027 | 531 |
| NCT07476118Obesity · United States | 1 | Active, not recruiting | Feb 2027 | 150 |
| NCT07420283Opioid-Related Disorders · United States, Canada, Puerto Rico and more | 2 | Recruiting | Mar 2028 | 465 |
| NCT07412756Depressive Disorder, Major · United States, Australia, Brazil and more | 3 | Recruiting | Feb 2028 | 1,000 |
| NCT07410507Schizophrenia · United States, Argentina, Brazil and more | 2 | Recruiting | Nov 2027 | 450 |
| NCT07286175Bipolar Disorder · United States, Argentina, Brazil and more | 2 | Recruiting | Nov 2027 | 400 |
| NCT07223840Smoking · United States, China, Japan | 2 | Recruiting | Feb 2027 | 222 |
| NCT07219173Asthma · United States, Argentina, Brazil and more | 2 | Recruiting | Apr 2028 | 531 |
| NCT07219966Alcoholism · United States, Belgium, China and more | 3 | Recruiting | Apr 2028 | 1,100 |
| NCT07219953Alcoholism · United States, Belgium, China and more | 3 | Recruiting | Apr 2028 | 1,100 |
| NCT07202871Healthy · Singapore | 1 | Completed | Jul 17, 2026 | 47 |
| NCT07165015Renal Insufficiency · United States, New Zealand | 1 | Completed | Apr 16, 2026 | 31 |
| NCT07165002Hepatic Insufficiency · Hungary, New Zealand, Slovakia | 1 | Recruiting | Nov 2026 | 32 |
| NCT06606106Overweight · United States | 1 | Active, not recruiting | Nov 2026 | 302 |
| NCT04648865Healthy · Japan | 1 | Completed | Jun 4, 2021 | 40 |
How it is read
Names in the registry
- “Brenipatide”, 11 entries
- “LY3537031”, 10 entries
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 3 studies
- Irritable Bowel Syndrome, 2 studies
- Alcoholism, 2 studies
- Obesity, 2 studies
- Asthma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.